Moreover, 71.2% of patients with grade IV (GBM) had high positive staining for SERBP1, significantly more than grade I (7.1%), grade II (40.7%), and grade III (61.1%) gliomas (P < 0.001) (Fig. 1c, Additional File 4: Table S3). Here, SERBP1 is linked to glioblastoma.